Association of clinical covariates with likelihood of detection by 68Ga PSMA-PET/CT
| Variable | Odds ratio (95% CI) | P |
| pT-category | ||
| pT3a vs. pT2 (reference) | 1.91 (0.48–8.87) | 0.362 |
| pT3b vs. pT2 (reference) | 1.33 (0.32–4.99) | 0.670 |
| pN-category | ||
| pN1 vs. pN0 (reference) | 2.10 (0.28–43.4) | 0.524 |
| Margin status | ||
| Positive vs. negative (reference) | 1.58 (0.42–6.24) | 0.5 |
| Gleason score | ||
| 8-9 (ISUP G4-5) vs. 5-7
(ISUP G1-3; reference) | 0.70 (0.24–2.07) | 0.499 |
| Duration between RadP to BCR | ||
| Continuous
(per month increase) | 1.01 (0.99–1.06) | 0.395 |
| ≤ 6 vs. > 6 (month; reference) | 1.13 (0.26–5.16) | 0.868 |
| PSA at time of 68Ga
PSMA-PET/CT | ||
| Continuous
(per 0.1 ng/ml increase) | 1.134 (1.046–1.299) | 0.017* |
| > 1.0 vs. ≤ 1.0
(ng/mL; reference) | 10.84 (3.03–88.4) | 0.002* |
| PSA doubling time | ||
| Continuous
(per month increase) | 0.974 (0.923–1.04) | 0.362 |
| ≤ 9 vs. > 9
(month; reference) | 0.336 (0.036–1.917) | 0.232 |
ISUP, International Society for Urological Pathology grading system for prostate cancer based on Gleason score; RadP, radical prostatectomy; BCR, biochemical relapse; PSA, prostate specific antigen. *Significant associations highlighted in bold italics.